- D-Lay MS trial evaluated high-dose cholecalciferol efficacy in multiple sclerosis.
- The vitamin D group showed reduced disease activity compared to the placebo group.
- Serious adverse events were comparable between groups.
- The trial enrolled participants between 2013-2020, with follow-up until January 2023.
- High-dose vitamin D may be promising for managing multiple sclerosis.
Source: JAMA
